Results 1 to 10 of about 17,632 (202)

Effects of Abatacept in patients with rheumatoid arthritis and cancer risk [PDF]

Reviews in Clinical Medicine, 2023
Introduction: As a chronic autoimmune disease, Rheumatoid arthritis (RA) affects the joints. Studies have shown a complex and challenging link between cancer and RA.
Saba Homapoor, Maryam Sahebari, Mandana Khodashahi   +2 more
doaj   +1 more source

Two-year clinical outcomes after discontinuation of long-term golimumab therapy in Korean patients with rheumatoid arthritis [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims The aim of this study was to investigate long-term post-discontinuation outcomes in patients with rheumatoid arthritis (RA) who had been treated with tumor necrosis factor-α inhibitors (TNF-αi) which was then discontinued.
Kichul Shin, Hyun Mi Kwon, Min Jung Kim, Myung Jae Yoon, Hyun Gyung Chai, Seong-Wook Kang, Won Park, Sung-Hwan Park, Chang Hee Suh, Hyun Ah Kim, Seung-Geun Lee, Choong Ki Lee, Sang-Cheol Bae, Yong-Beom Park, Yeong Wook Song   +14 more
doaj   +1 more source

Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II/III trials

Arthritis Research & Therapy, 2023
Background This study sought to evaluate the efficacy and safety of tofacitinib in patients with rheumatoid arthritis with distinct treatment histories. Methods Pooled phase II/III trial data from patients who received tofacitinib 5 or 10 mg twice daily ...
John Tesser, Ahmet Gül, Ewa Olech, Kurt Oelke, Tatjana Lukic, Kenneth Kwok, Abbas Ebrahim   +6 more
doaj   +1 more source

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity [PDF]

The Korean Journal of Internal Medicine, 2020
Background/Aims The objective of this study was to compare changes in the simplified disease activity index (SDAI) between biologic (b) and conventional (c) disease-modifying antirheumatic drugs (DMARD) users with seropositive rheumatoid arthritis (RA ...
Kichul Shin, Sung Soo Kim, Sang-Heon Lee, Seung-Jae Hong, Sung Jae Choi, Jung-Yoon Choe, Seung-Geun Lee, Hoon-Suk Cha, Eun Young Lee, Sung-Hwan Park, Jin-Wuk Hur, Sung Soo Na, Chang-Hee Suh, Min Wook So, Seung Won Choi, Dong-Hyuk Sheen, Won Park, Shin-Seok Lee, Wan Hee Ryu, Jin Seok Kim, Jung Soo Song, Hye Soon Lee, Seong Ho Kim, Dae-Hyun Yoo   +23 more
doaj   +1 more source

Antirheumatic Agents

, 2012
europepmc   +2 more sources

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Cardiovascular disease is the most common cause of death in patients with rheumatoid arthritis. It is believed that using disease‐modifying antirheumatic drugs (DMARDs) to control inflammation can reduce the risk of cardiovascular disease.
Chung‐Yuan Hsu, Yu‐Jih Su, Jia‐Feng Chen, Chi‐Chin Sun, Tien‐Tsai Cheng, Tzu‐Hsien Tsai, Shang‐Hong Lin, Cheng‐Chieh Chang, Tien‐Hsing Chen   +8 more
doaj   +1 more source

Coronavirus disease 2019 in patients with rheumatic immune-mediated diseases in a single University Hospital, matched case-control study and literature review

Frontiers in Medicine, 2022
BackgroundCOVID-19 may present different degrees of severity. Viral infections in patients with rheumatic inflammatory diseases (R-IMID) trend to present more severe disease.
David Martínez-López, Ivan Ferraz-Amaro, Diana Prieto-Peña, Lara Sánchez-Bilbao, Alba Herrero-Morant, Carmen Álvarez-Reguera, Fabricio Benavides-Villanueva, Cristina Corrales-Selaya, Martín Trigueros-Vázquez, Miguel Ángel González-Gay, Ricardo Blanco   +10 more
doaj   +1 more source

Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019 [PDF]

The Korean Journal of Internal Medicine, 2022
Background/Aims The preventive role of hydroxychloroquine (HCQ) on coronavirus disease 2019 (COVID-19) remains unclear. The aim of this study was to examine the effects of HCQ and other immunosuppressive drugs on the incidence of COVID-19.
Ji-Won Kim, Sang Gyu Kwak, Hwajeong Lee, Seong-Kyu Kim, Jung-Yoon Choe, Sung-Hoon Park   +5 more
doaj   +1 more source

Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

BMC Rheumatology, 2020
Background Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate ...
Shubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, Firdaus Fatima, Vamsi Krishna Bandi, Pankaj Thakur, Bala Reddy, Sreenivasa Chary, Leela Talluri, Ajay Gupta, Amit Ramchandra Kale, Anil Kumar Gupta, Ashok Kumar P, Diwakar Reddy, Younus Mohammed, Soma Shekar, Sudheer T, Vijay G. Goni, Vishnu Sharma, Vishwanath Yeligod   +19 more
doaj   +1 more source

Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund's adjuvant arthritis model: Downregulation of IL-6/JAK2/STAT3 signaling pathway

Saudi Pharmaceutical Journal, 2020
Rheumatoid arthritis (RA) is an autoimmune inflammatory disease, which is accompanied by progressive joint damage and disability. The intolerability of conventional antirheumatic drugs by some patients necessitates the search for effective antirheumatic ...
Amany A. Azouz, Esraa Saleh, Ali A. Abo-Saif   +2 more
doaj   +1 more source